We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BBAS3:BMFBOVESPABanco do Brasil S.A. Analysis

Data as of 2026-03-11 - not real-time

R$25.14

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Banco do Brasil trades at R$25.14, roughly half of its DCF‑derived fair value of R$48.75, indicating a sizable discount. The stock’s price‑to‑earnings ratio of 10.5 is well below the industry average of 17.3, and its price‑to‑book of 0.76 underscores the undervalued status. Despite an 8% year‑over‑year revenue contraction, the bank maintains a solid operating margin of 23% and a profit margin of 15.5%. Forward earnings per share are projected at R$5.38, cutting the forward PE to 4.7, which signals improving earnings visibility. The dividend yield of 1.12% is supported by a low payout ratio of 20%, and the company holds ample cash of R$24.4 bn, suggesting sustainability. Analyst consensus remains neutral with a “hold” rating, reflecting cautious optimism amid modest growth prospects.
Technically, the price sits just above the 50‑day SMA (R$24.16) but below the 20‑day SMA (R$25.96), placing it in a narrow consolidation zone. The MACD histogram is negative and the signal line is bearish, while the RSI at 48 indicates neither overbought nor oversold conditions. Current support at R$24.24 and resistance at R$27.81 provide a defined range, and decreasing volume suggests limited short‑term momentum. Volatility remains high at 31% over the past 30 days, yet the beta of 0.21 points to low systematic risk relative to the market. Recent news highlights a profit rebound and a confirmed dividend distribution, reinforcing the earnings upside hinted by the fundamentals. Combined, these factors point to a modest upside potential of about 7% while keeping downside risk contained.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 6/10

Key Factors

  • price below fair value
  • support level intact
  • negative MACD suggests caution

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • undervalued multiples
  • sustainable dividend
  • profit rebound expectations

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • state‑backed stability
  • low beta and systematic risk
  • consistent cash generation

Key Metrics & Analysis

Financial Health

Revenue Growth-8.00%
Profit Margin15.54%
P/E Ratio10.5
ROE8.75%
ROA0.69%
P/B Ratio0.8
Op. Cash FlowR$135.0B
Industry P/E17.3

Technical Analysis

TrendBullish
RSI47.8
SupportR$24.24
ResistanceR$27.81
MA 20R$25.96
MA 50R$24.16
MA 200R$22.09
MACDBearish
VolumeDecreasing
Fear & Greed Index76.57

Valuation

Fair ValueR$48.75
Target PriceR$26.94
Upside/Downside7.15%
GradeUndervalued
TypeValue
Dividend Yield1.12%

Risk Assessment

Beta0.21
Volatility31.24%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.